期刊
AMERICAN JOURNAL ON ADDICTIONS
卷 15, 期 1, 页码 105-110出版社
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/10550490500419169
关键词
-
资金
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007288, F32DA018501, P50DA015369] Funding Source: NIH RePORTER
- NCRR NIH HHS [M01 RR001070, RR01070] Funding Source: Medline
- NIDA NIH HHS [F32 DA018501, T32 DA007288, P50 DA015369, DA018501, DA015369] Funding Source: Medline
A double-blind placebo-controlled crossover Phase I trial was conducted to assess the safety and tolerability of N-Acetylcysteine (NAC) in healthy, cocaine-dependent humans. Thirteen participants attended a three-day hospitalization in which they received placebo or NAC. Subjects were crossed over to receive the opposite medication condition during a second three-day hospitalization, which occurred the following week. Across placebo and NAC conditions, only mild side effects were noted, and the number of subjects reporting side effects did not differ. There were trends for a greater reduction in withdrawal symptoms and craving within the NAC condition. These preliminary results suggest that NAC is well tolerated in healthy, cocaine-dependent individuals and may reduce cocaine-related withdrawal symptoms and craving.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据